Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) shares were trading lower Tuesday, closing down 14.61% at 38 cents. The stock is pulling back after gaining as much as 60% during Monday’s session after the company reported second-quarter financial results. The company early Tuesday also said it initiated a Phase 2 trial of TNX-1300, a treatment for acute cocaine intoxication, aiming to rapidly degrade cocaine in the body. The study, supported by NIDA and with FDA Breakthrough Therapy designation, will test the safety and effectiveness of TNX-1300 in 60 patients across six U.S. emergency depart…